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1. Introduction
  Drug resistance in Mycobacterium tuberculosis (M. 
tuberculosis) has become a global problem in recent 
years and the emergence of multi drug resistant strains 
has dramatically increased the mortality worldwide. No 
tuberculosis-specific drug has been discovered for more 
than four decades. Mycobacterium bovis BCG (M. bovis BCG), 
an anti-TB vaccine, developed by Calmette and Guerin, has 
been used worldwide till date. But its protective efficacy 
against the pathogen varies from individual to individual. 
During infection, M. tuberculosis relies heavily on fatty 
acid metabolism for both energy supply and for synthesis 
of essential biomolecules required for its growth and 
survival in the living host[1-3]. Propionyl-CoA generated 
along with acetyl-CoA during the breakdown of odd-chain 
fatty acids and amino acids are reported to be potentially 
toxic to the mycobacteria[4,5]. In mycobacteria, propionyl-
CoA metabolism is linked to synthesis of essential lipid 
virulence factors like phthiocerol dimycocerosate (PDIM) 
and sulfolipid-1 (SL-1)[6]. M. tuberculosis metabolizes 
propionyl-CoA through methylcitrate cycle. Mycobacterial 
methylcitrate cycle consists of 2-methylcitrate synthase 
(Rv1131) and methylcitrate dehydratase (Rv1130) but do 
not contain a dedicated methylisocitrate lyase (MCL)[7,8]. 
Objective: To clone, express and purify 2-methylcitrate synthase (Rv1131) gene of 
Mycobacterium tuberculosis (M. tuberculosis) and to study its structural characteristics using 
various bioinformatics tools. Methods: Rv1131 gene was amplified by polymerase chain reaction 
using M. tuberculosis H37Rv genomic DNA and cloned into pGEM-T easy vector and sequenced. 
The gene was sub-cloned in pET28c vector, expressed in Escherichia coli BL21 (E. coli BL21) 
(DE3) cells and the recombinant protein was identified by Western blotting. The protein was 
purified using Nickel affinity chromatography and the structural characteristics like sub-cellular 
localization, presence of transmembrane helices and secondary structure of the protein were 
predicted by bioinformatics tools. Tertiary structure of the protein and phylogenetic analysis 
was also established by in silico analysis. Results: The expression of the recombinant protein 
(Rv1131) was confirmed by western blotting using anti-HIS antibodies and the protein was 
purified from the soluble fraction. In silico analysis showed that the protein contains no signal 
peptide and transmembrane helices. Active site prediction showed that the protein has histidine 
and aspartic acid residues at 242, 281 & 332 positions respectively. Phylogenetic analysis showed 
100% homology with major mycobacterial species. Secondary structure predicts 2-methylcitrate 
synthase contain 51.9% alpha-helix, 8.7% extended strand and 39.4% random coils. Tertiary 
structure of the protein was also established. Conclusions: The enzyme 2-methylcitrate synthase 
from M. tuberculosis H37Rv has been successfully expressed and purified. The purified protein 
will further be utilized to develop assay methods for screening new inhibitors.
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Isocitrate lyase of glyoxylate pathway does MCL activity 
by its capability to accommodate both the substrates 
(methylisocitrate and isocitrate) in its active site[9]. 
2-methylcitrate synthase catalyzes the condensation of 
propionyl-CoA with oxaloacetate to form 2-methylcitrate. 
Accumulation of 2-methylcitrate inside the cells is 
reported to inhibit the bacterial cell growth and blocks 
gluconeogenesis[10,11]. Enzymes involved in methylcitrate 
cycle do not have homologue in humans and thus 
considered as potential target for new anti-tubercular drug 
development. To study the function of 2-methylcitrate 
synthase enzyme, we expressed the protein in Escherichia 
coli BL21 (E. coli BL21) (DE3) and purified using Ni-
NTA affinity chromatography. Physical and structural 
characteristics of the purified protein were predicted using 
various bioinformatics tools.
2. Materials and methods
2.1. Bacterial strains, plasmids and chemicals
  E. coli DH5毩 was used for general cloning procedures 
and E. coli BL21 (DE3) was used for expression studies. M. 
tuberculosis H37Rv genomic DNA was purchased from TCGA, 
New Delhi. T4 DNA ligase, restriction/ DNA modifying 
enzymes were obtained from New England Biolabs (USA). 
Oligonucleotide primers were synthesized from Sigma, 
Inc. (USA). Plasmid pET28c was purchased from Novagen 
(Germany). Ni-NTA agarose and other PCR purification/ 
Plasmid isolation kits were obtained from Qiagen (Germany). 
Phenylmethanesulfonylfluoride (PMSF), lysozyme and 
all analytical grade chemicals were either from Himedia 
chemicals (India). Standard recombinant DNA techniques 
used were as described elsewhere[17]. 
2.2. PCR amplification of Rv1131 
  The nucleotide sequence of Rv1131 gene was retrieved 
from NCBI (http:// www.ncbi.nlm.nih.gov) for designing gene 
specific primers. PCR was performed using M. tuberculosis 
H37Rv genomic DNA as template (DMSO was added to the 
PCR reaction mixture to lower the melting temperature since 
M. tuberculosis H37Rv Genomic DNA is GC rich template). 
Rv1131 gene was amplified using gene-specific primers 
(Table 1) containing BamH栺 (Forward primer) and Hind栿 
(Reverse primer) restriction sites. Phusion襆High-Fidelity 
DNA Polymerase  was used to amplify the gene under 
following conditions: 95 曟 for 5 min, 25 cycles (95 曟 1 min; 
55 曟 1 min; 72 曟 1 min), and final extension of 72 曟 for
10 min. The PCR products were analyzed on a 1.2% agarose 
gel stained with ethidium bromide.  
Table 1
Primers used in the study.
Primer name Sequence details (5’- 3’) **
 Rv1131 forward ATTCCACCAGGATCCTTTCGATG 
 Rv1131 reverse GAGAAAGCTTATGGCCCATAAGAG
 T7 promoter TAATACGACTCACTATAGGG
 T7 terminator CTAGTTATTGCTCAGCGGTG
** Restriction sites in the primer have been underlined.
2.3. Cloning of Rv1131 gene in E. coli 
  PCR products were gel purified and cloned into pGEM-T 
easy vector and sequenced. The plasmid containing Rv1131 
gene was digested with BamH栺and Hind栿, restriction 
enzymes and the digested gene product was gel purified 
and ligated into expression vector pET28c (digested with the 
same enzymes) overnight at 16 曟. The ligated products were 
then transformed into E. coli DH5毩 cells using standard 
protocol. Colonies were screened by PCR using T7 Promoter 
and T7 Terminator primers (Table 1) and the recombinant 
plasmid was isolated from the positive colonies by alkaline 
lysis method. The recombinant plasmid was then subjected 
to restriction analysis using BamH栺and Hind栿 restriction 
enzymes. 
2.4. Expression of Rv1131 gene in E. coli
  The recombinant plasmid pET28c-Rv1131 was transformed 
into E. coli BL21 (DE3) cells for expression studies. A single 
colony of E. coli BL21 (DE3) containing pET28c-Rv1131 was 
inoculated in 5 mL of LB medium containing kanamycin 
(50 毺g/mL) and grown at 37 曟 overnight. One mL of this 
culture was added in 100 mL fresh LB medium containing 
kanamycin (50 毺g/mL) at 37 曟 until A600 0.6 was reached. To 
the growing culture of E. coli BL21 (DE3) containing pET28c-
Rv1131, IPTG was added to a final concentration of 1 mM 
and incubated at 30 曟 for 4 h. After induction, cells were 
harvested by centrifugation at 8 000 g for 10 min and the 
total proteins of the control and induced cells were analyzed 
by 12% SDS PAGE. The proteins were visualized by staining 
the gel with Coomasie blue (0.05%) for 30 min in a rocking 
shaker. 
2.5. Purification and Western Blotting
 E. coli BL21 (DE3) cells transformed with pET28c-Rv1131 
were grown at 37 曟 in LB broth containing kanamycin
(50 毺g/mL) to an A600 of 0.6 and the expression was induced 
by the addition of 1 mM IPTG for 4 h at 30 曟. Cells from
500 mL culture were resuspended in 5 mL of buffer A
(20 mM tris-HCL, pH 8.0, 500 mM NaCl, 30 mM imidazole, 
1 mM PMSF and 10 毺g/mL Lysozyme). After one cycle of 
freeze-thaw, cells were lysed by sonication (30 s pulse 
暳 30 s pause). The soluble fraction was separated by 
centrifugation at 15 000 rpm for 30 min at 4  曟 and loaded 
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on to a pre-equilibrated 2 mL (bed volume) Ni-NTA affinity 
column. After washing the column with 30 bed volumes of 
buffer B (50 mM tris-Cl, 500 mM NaCl, 40 mM imidazole, 
pH 8.0) at a flow rate of 1.0 mL/min, the bound protein 
was eluted in buffer C (50 mM tris-Cl, 300 mM NaCl and 
200 mM imidazole, pH 8.0). The purified proteins were 
quantified using Bradford method. For western blotting, 
the purified protein was electrophoresed on SDS-PAGE 
(12%) and transferred to PVDF membrane. After blocking, 
the membrane with Bovine serum albumin (5%) for 90 min, 
the membrane was probed with 1:5 000 dilution of anti-
HIS mouse IgG antibody followed by HRP-conjugated goat 
anti-IgG antibody. The blot was developed using 3, 3’-
Diaminobenzidine substrate. 
2.6. In silico analysis of Rv1131 gene and 2-methylcitrate 
synthase protein 
  The nucleotide and protein sequences analyzed by in silico 
methods were retrieved from NCBI database (http:// www.
ncbi.nlm.nih.gov). The multiple sequence alignment was 
carried out using ClustalW Program (http://www.ebi.ac.uk/
Tools/msa/clustalw2/) and the alignment file was used to 
generate phylogenetic relationship using MEGA 5.1Beta 
software. Signal peptides and subcellular localization was 
predicted by SignalP (http://www.cbs.dtu.dk/services/
SignalP/) and TMHMM (http://www.cbs.dtu.dk/services/
TMHMM-2.0/) program respectively. Secondary structure 
of the protein was predicted using PredictProtein Program 
(https://www.predictprotein.org/). Tertiary structure of the 
protein was established using SWISS-MODEL server (http://
swissmodel.expasy.org/) based on homology modeling and 
analysed by Rasmol software (http://rasmol.org/OpenRasMol.
html). 
3. Results
3.1. Cloning of Rv1131 gene
  Rv1131 gene was amplified by PCR (Figure 1A). A 1.2 kb 
DNA fragment containing an open reading frame of 393 
amino acids was obtained. The gene was then cloned into 
pGEM-T easy vector and screened by blue/white screening 
method. The sequence of positive recombinant plasmid 
was verified by DNA sequencing. The positive recombinant 
plasmid was digested with BamH栺and Hind栿 restriction 
enzymes and the gene product was gel purified and ligated 
with pET28c vector (digested with the same enzymes) and 
transformed into E. coli DH5毩. Colonies were screened by 
PCR using T7 promoter and T7 terminator primers (Table 
1) to identify recombinant colonies. Recombinant plasmid 
was isolated from the positive colony and subjected to 
restriction analysis using BamH栺and Hind栿, restriction 
enzymes (Figure 1B). The pET28c vector was chosen 
because it contains N-terminal 6暳His Tag which facilitates 
purification by Nickel affinity chromatography.  
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Figure 1. PCR amplification of Rv1131 gene and restriction 
endonuclease analysis of recombinant pET28c-Rv1131. 
(A) Rv1131 gene amplified by PCR using M. tuberculosis H37Rv genomic 
DNA. Lane M, 100 bp DNA Ladder;  lane 1, Rv1131 PCR product.
(B) Recombinant plasmid pET28c-Rv1131 was identified by restriction 
analysis using BamH栺 and Hind栿 enzymes. Lane M, 1 kb DNA 
Ladder; Lane 1, pET28c-Rv1131 digested with BamH栺 and Hind栿; 
Lane 2, undigested pEt28c-Rv131 plasmid.
3.2. Expression of 2-methylcitrate synthase 
  E. coli BL21 (DE3) was transformed with pET28c-
Rv1131 recombinant plasmid for 2-methylcitrate synthase 
production. Expression of 2-methylcitrate synthase was 
induced by adding IPTG to a final concentration of 1 mM at 
lower incubation temperature (30 曟) for 4 h. The induced 
protein was observed by analyzing the IPTG added cells 
along with control cells (IPTG not added) by 12% SDS-PAGE 
stained with Coomasie blue G250 and as expected a band at 
43 kDa was observed (Figure 2A). The solubility and cellular 
localization of the protein was analyzed by sonication of the 
cell pellet and subjecting the soluble and insoluble fractions 
to SDS-PAGE. 2-methylcitrate synthase was found to be 
present predominantly in the soluble fraction. Nickel affinity 
chromatography was used for purifying the protein from the 
soluble fraction. 
3.3. Purification and identification of 2-methylcitrate 
synthase
 The 2-methylcitrate synthase was purified from the soluble 
fraction. The supernatant soluble fraction was incubated with 
Ni-NTA agarose matrix overnight at 4 曟 and then loaded into 
the column. After washing the column with wash buffer, the 
bound proteins were eluted using elution buffer containing 
imidazole. The eluted fractions were then analyzed by SDS-
PAGE. The analysis showed a single band at 43 kDa in 
the gel (Figure 2B). The eluted protein was confirmed by 
western blotting using anti-His IgG antibodies. The eluted 
fractions were subjected to SDS PAGE and transferred to 
PVDF membrane and probed using anti-His IgG antibodies. 
The blot was developed using 3,3’-diaminobenzidine 
and it showed a single band at 43 kDa (Figure 2C). 
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Figure 2. SDS-PAGE analysis and Western blotting identification of 
2-methylcitrate synthase protein expressed in E. coli BL21 (DE3) cells.
(A) SDS-PAGE analysis of total proteins, soluble and insoluble 
fractions expressed. Lane M, protein molecular mass standards; lane 
1, cell lysate of bacteria transformed with pET28c-Rv1131 without 
induction; lane 2, cell lysate of bacteria transformed with pET28c-
Rv1131 with IPTG (1 mM) induction for 4 h; lane 3, induced supernatant 
fraction; lane 4, induced pellet fraction. 
(B) SDS-PAGE analysis of purified 2-methylcitrate synthase protein. 
Lane M, protein molecular mass standards; lane 2, the protein purified 
from the supernatant fraction. 
(C)Western blotting analysis of N-terminal 6暳His tagged 
2-methylcitrate synthase protein. Lane 1, N-terminal 6暳His tagged 
2-methylcitrate synthase protein. The arrows indicates the location of 
recombinant protein.
3.4. Analysis of structural characteristics of 2-methylcitrtae 
synthase by in silico methods
  2-methylcitrate synthase consists of 393 amino acids with 
a theoretical molecular mass of 42.9 kDa and pI value of 
8.61. Sequence alignment reveals 2-methylcitrate synthase 
of M. tuberculosis H37Rv to share 100% homology with 
M. tuberculosis H37Ra and M. tuberculosis CDC151 and 
shows 70% with other mycobacterial species (Figure 3). 
2-methylcitrate synthase does not show the presence of 
signal peptide, transmembrane helices and was found to be 
located outside the membrane (Figure 4). An N-glycosylation 
site and an N-myristoylation site also have been predicted 
in the protein.  Secondary structure prediction showed that 
the protein has 51.9% alpha-helix, 8.7% extended strand and 
39.4% random coils. The protein was also predicted to have 
Protein kinase C phosphorylation site at 53, 90, 96, 293, 303 
residues respectively and Casein kinase 栻 phosphorylation 
sites at 21, 82, 90, 195, 222, 303, residues respectively. The 
tertiary structure of 2-methylcitrate synthase protein was 
also established based on homology modeling (Figure 5).
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Paracoccus denitrificans
Pseudomonas putida
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Figure 3. Evolutionary tree analysis of 2-methylcitrate synthase from 
other microorganisms. 
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Figure 4. Sub-cellular localization and transmembrane helices 
prediction of 2-methylcitrate synthase.
Figure 5. Tertiary structure of 2-methylcitrate synthase of M. tuberculosis.
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4. Discussion
  The genome of Mycobacteria consists of significant number 
of open reading frames (ORFs) that encode proteins that 
play a role in the growth or survival of the bacterium inside 
macrophages[7,12]. Multidrug-resistant strains are on the 
rise, and its infection is often associated with HIV infection. 
Mycobacterial persistence inside the host macrophages 
remains the biggest challenge for developing new drugs 
against the pathogen. So far, the drugs which are available in 
the treatment of tuberculosis target only the actively growing 
bacteria. Metabolic adaptations are required for long term 
persistence of mycobacteria inside the host. M. tuberculosis 
shifts its energy source from glucose to fatty acids because 
it has the ability to induce formation of foamy macrophages 
which are loaded with large number of lipid-containing 
bodies[13]. Methylcitrate cycle, which enables M. tuberculosis 
to utilize fatty acids, has been identified as potential 
metabolic pathway that could be targeted by new drugs[14,15]. 
Methylcitrate cycle is also known to be an important 
pathway for anaplerotic replenishment of tricarboxylic 
acid cycle intermediates and for gluconeogenesis in most 
of the cells[16]. In M. tuberculosis, it has been reported 
that tricarboxylic acid (TCA) intermediates are critical for 
infection[16]. The focus of this study is to identify potential 
new drug targets in M. tuberculosis. 2-methylcitrate synthase 
enzyme is one of the key enzymes of the most common 
propionyl-CoA metabolizing pathway in micro-organisms 
and is a conserved enzyme. Targeting this enzyme therefore 
could have multiple effects in M. tuberculosis: build-
up of toxic propionyl CoA, inhibition of gluconeogenesis 
and on the overall efficiency of TCA because of its role in 
anaplerotic replenishment of the TCA intermediates. 
  Through bioinformatics tools its localization, modification 
sites and possible active sites residues have been identified 
which could enable researchers to develop new anti-
tuberculosis drugs by targeting 2-methylcitrate synthase 
enzyme.  
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